Japan
BrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath’s Novel Allogeneic iPSC Derived Cell Therapy Platform across Multiple Indications
BrightPath Biotherapeutics Co., Ltd. (TYO: 4594), a clinical stage biotechnology company focused on the development of cell therapies derived from invariant natural killer T (iNKT) cells, and Artisan Bio. Inc, a precision genome engineering and drug discovery company, today announced they have signed a research and licensing agreement to accelerate BrightPath's next-generation iNKT cell therapies to clinic.
Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held May 5-8, 2023 in San Diego, California.
Astellas Enters into Definitive Agreement to Acquire Iveric Bio
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, "Iveric Bio") today announced that on April 29, 2023 (Japan time), the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash for a total equity value of approximately US$5.9 billion (the "Acquisition").
